A Pilot Study of Pivanex in Patients With Malignant Melanoma
Status:
Terminated
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
This pilot study will assess the safety and efficacy of Pivanex alone in patients with
malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2
(IL-2). Pivanex is an investigational agent.